Boston Common Asset Management LLC has lowered its stake in Novartis, while investment firms like Park Avenue Securities LLC and CWA Asset Management Group LLC have increased theirs. Despite a drop in sales, Novartis remains a top value stock for the long-term with potential for growth. Federal court's temporary block on generic Entresto further strengthens Novartis in the market. Meanwhile, the company’s value stance has been commended by several experts including Zacks Research and Flywheel Private Wealth LLC. These developments are expected to beneficially impact Novartis’s future performance and overall stock evaluation. The pharmaceutical giant recently made significant business moves, including a $2.9 Billion licensing agreement with PTC Therapeutics and a collaboration with Schrödinger, both indicating an innovative streak in the company. However, Novartis faced a market setback following disappointing Pluvicto data. It's yet to be seen how these factors will weigh in on Novartis's value.
Novartis Stocks News Analytics from Tue, 23 Apr 2024 07:00:00 GMT to Sat, 18 Jan 2025 15:13:43 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -1
